Advanced Biomedical Research · 2018 · 11 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyBiochemical PharmacologyDrug DiscoveryStructure-activity RelationshipsAntiparasitic PharmacologyStructure-activity Relationship AnalysisAntileishmanial ChemotherapyAntileishmanial TreatmentHydroxyl FunctionalizationLeishmaniasis PathogenesisMedicinal Chemistry ApplicationsRegioselective OxidationStructure - Activity Relationship OptimizationTreatment Of Leishmaniasis
Background: Today, leishmaniasis is a widespread, infectious parasitic disease caused by Leishmania spp. Natural-derived compounds are likely to provide a valuable source of new pharmaceuticals, and among them, quercetin derivatives may have antileishmanial effects. The antileishmanial activity of 3,5,7,3’,4’-pentahydroxyflavonol (quercetin) derivatives is partly attributed to the position and pKa of phenolic or catechol hydroxyl groups. Therefore, to optimize their leishmanicidal effect, the structural features of quercetin and its derivatives were improved by acylation or alkylation of hydroxyl groups and changing their pKa and consequently their activities. Materials and Methods: In this study, during a regioselective method, quercetin derivatives were synthesized. The structures of synthesized compounds were confirmed by mass, IR, 1 H-, and 13 C-NMR spectral data. The antileishmanial activities of compounds 1–6 were compared with glucantime as the standard drug against promastigotes of Leishmania major using standard cell-based leishmanicidal assay. Results: In this study, during a regioselective method, two 7-O-quercetin derivatives (5 and 6), and three quercetin acetate derivatives (2, 3, and 4) were synthesized. In detail, the IC 50 values found against L. major were (1) 2.5 ± 0.92; (2) 2.85 ± 0.99; (3) 15.5 ± 1.95; (4) 13.5 ± 3.5; (5) 2.6 ± 0.57; and (6) 1.3 ± 0.35 μM while IC 50 value of glucantime as the standard drug was 88.5 ± 9.47 μM. Conclusions: The present study showed an effective antileishmanial activity of quercetin semisynthetic compounds (1–6) against in vitro promastigotes of L. major . Among them, quercetin analogs with more lipophilic and iron-chelating activity showed more antiparasite activity.
15
Deniz Taşdemir, Marcel Kaiser, Reto Brun et al. · Antimicrobial Agents and Chemotherapy · 2006 · 515 citations · Full text
Current scenario of drug development for leishmaniasis.
Simon L. Croft, Karin Seifert, Vanessa Yardley · PubMed · 2006 · 392 citations · Full text
Virginia Iniesta, Luis Carlos Gómez-Nieto, Inés Corraliza · The Journal of Experimental Medicine · 2001 · 266 citations · Full text
Bidyottam Mittra, Asim Saha, Arnab Roy Chowdhury et al. · Molecular Medicine · 2000 · 241 citations · Full text
Fernanda Fonseca-Silva, Job D. F. Inacio, Marilene M. Canto‐Cavalheiro et al. · PLoS ONE · 2011 · 197 citations · Full text